N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Contrast Induced NephropathyCritically Ill
Interventions
DRUG

N-acetylcysteine

Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).

DRUG

D5W Placebo

Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).

Trial Locations (2)

N6A 4G5

London Health Sciences Centre - Victoria Hospital, London

N6A 5A5

London Health Sciences Centre - University Hospital Campus, London

All Listed Sponsors
collaborator

Martin, Claudio M., M.D.

INDIV

collaborator

Fran Priestap

UNKNOWN

lead

Unity Health Toronto

OTHER

NCT00830193 - N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography | Biotech Hunter | Biotech Hunter